Actavis strikes South Korean distribution deal
This article was originally published in Scrip
Actavisis building up its presence in Asia through a new distribution agreement with the South Korean company J&M Pharma. The exclusive deal covers a number of products and marks the Icelandic generics firm's expansion into what it says is a fast-growing market. Actavis already sells its products in several countries in the Asia-Pacific region including China, Taiwan and Australia.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.